Technology

Quolet’s unique and proprietary delivery technology platform, Soli-Sol™, is designed to enhance the performance of certain compounds in consumable and topical products. The patented technology has been shown to improve the way active pharmaceutical ingredients (“APIs”) are absorbed, distributed and bound to the intended targets in the body.

The table below outlines the advantages that Quolet’s Soli-Sol™™ delivery system exhibits over traditional delivery systems:

Attribute	Traditional Formulation	SoliSol ™ Technology	Evidence
Stability	CBD oxidizes quickly creating a very short shelf life	SoliSol™ encapsulates and protects CBD from oxidation	Cognissol™ stability studies of drug product
Stomach environment	CBD largely destroyed by stomach acid	Formulation protection from acid due to self emulsification	Long chain FA structures have been shown to be an effective delivery vehicle to the colon offering gastric protection and rapid transport across cell membranes
Liver bypass	CBD causes liver toxicity at high doses	Bypasses first-pass liver metabolism and travels directly into lymphatic system to target organs	Enterocyte/chylomicron delivery system is well documented in the literature and shown in Phase I PK Study
Bioavailability	Low CBD amount available in the blood	High doses to target organs are achieved by higher bioavailability and bypass of first-pass liver metabolism.	Phase I study demonstrates increased bioavailability.
Commercial	– Formulation – oil – No IP – FDA orphan indications – Treatment efficacy per mg is lower	– Formulation – Tablet or capsule – Formulation provides IP – Both orphan and non orphan indications – Treatment efficacy per mg is higher (reduced COGS)

The ultimate effect is that Soli-Sol™ increases the bioavailability of ingested compounds whilst potentially reducing or eliminated liver toxicity. The unique molecular structure of Soli-Sol™, as shown through animal modeling may better enables the API to reach its target receptors in the brain and other organs.